Repository logo
 
Publication

Biologic disease-modifying antirheumatic drugs survival in late-onset axial spondyloarthritis — data from a Portuguese registry

2025-04-01Journal article Restricted access
Simple item page
dc.contributor.authorSilva, Susana P.
dc.contributor.authorMonteiro, Beatriz
dc.contributor.authorOliveira, Cláudia Pinto
dc.contributor.authorCosta, Roberto Pereira da
dc.contributor.authorMatos, Carolina Ochôa
dc.contributor.authorLopes, Mariana Diz
dc.contributor.authorGomes, Carlos Marques
dc.contributor.authorBernardes, Miguel
dc.contributor.authorSantos, Mariana Emília
dc.contributor.authorGago, Laura
dc.contributor.authorAbreu, Catarina
dc.contributor.authorFraga, Vanessa
dc.contributor.authorMendes, Beatriz
dc.contributor.authorRocha, Margarida Lucas
dc.contributor.authorSoares, Catarina Dantas
dc.contributor.authorSilva, Cândida
dc.contributor.authorSantos, Helena
dc.contributor.authorValente, Paula
dc.contributor.authorSilva, Lígia
dc.contributor.authorEugénio, Gisela
dc.contributor.authorBarcelos, Anabela
dc.date.accessioned2025-06-25T08:50:29Z
dc.date.available2025-06-25T08:50:29Z
dc.date.issued2025-04-01
dc.description.abstractObjectives Although axial spondyloarthritis (axSpA) typically begins before age 45, late-onset axSpA (lo-axSpA) has been widely recognized. While existing literature describes this subgroup, data on therapeutic approaches remain limited. Therefore, we aimed to evaluate the efficacy and safety of biologic DMARDs in patients with lo-axSpA.Methods We conducted a retrospective, multicentre, national cohort study using data from the Rheumatic Diseases Portuguese Register. A cut-off age of 45 years was applied to define lo-axSpA. Group differences between early- and late-onset disease activity scores were evaluated, and drug survival was assessed over 12 months. Predictors of drug discontinuation were identified using a Cox proportional hazards model.Results In total, 2256 patients were included, of whom 260 (11.5%) had lo-axSpA. Patients with late-onset disease exhibited significantly higher scores in the Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index at baseline, 3, 6 and 12 months. Despite these differences, both groups showed proportional reductions in disease activity scores, indicating a continuous decrease in disease activity over time. Although the late-onset group had a higher discontinuation rate during the first 12 months of treatment, lo-axSpA was not associated with an increased risk of therapy discontinuation. The primary reason for treatment discontinuation in both groups was inefficacy, with low rates of infections and other adverse events observed across the cohort.Conclusion Our study demonstrated that lo-axSpA is not associated with reduced treatment efficacy or compromised safety.eng
dc.identifier.doi10.1093/rheumatology/keaf176
dc.identifier.eissn1462-0332
dc.identifier.issn1462-0324
dc.identifier.urihttp://hdl.handle.net/10400.1/27276
dc.language.isoeng
dc.peerreviewedyes
dc.publisherOxford University Press
dc.relation.hasversionhttps://academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheumatology/keaf176/8102809?redirectedFrom=fulltext&login=false
dc.relation.ispartofRheumatology
dc.rights.uriN/A
dc.subjectAxial spondyloarthritis
dc.subjectbDMARD
dc.subjectEfficacy
dc.subjectLate-onset axial spondyloarthritis
dc.subjectRegistry
dc.subjectSafety
dc.titleBiologic disease-modifying antirheumatic drugs survival in late-onset axial spondyloarthritis — data from a Portuguese registryeng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage9
oaire.citation.startPage1
oaire.citation.titleRheumatology
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Biologic disease-modifying antirheumatic drugs survival in late-onset axial spondyloarthritis.pdf
Size:
895.12 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.46 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ULS_10.1-MED-Artigos